| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Pogostone targets multiple pathways in bacteria, immune cells, and cancer cells. Its antibacterial activity involves inhibition of bacterial growth through mechanisms that may include disruption of cell membranes or inhibition of essential bacterial enzymes. Its immunosuppressive property is mediated by directly blocking T cell proliferation and altering the inflammatory cytokine profile. Its anticancer activity involves induction of apoptosis and autophagy. Its anti-inflammatory effects suggest modulation of inflammatory mediators. Its neuroprotective effects indicate protection of neuronal cells.
|
|---|---|
| ln Vitro |
Pogostone exhibits an inhibitory effect on HCT116 cells, as demonstrated by its IC50 value of 18.7±1.93 μg/mL. Its cytotoxicity is significantly reduced when applied to normal human embryonic kidney cells 293A and endothelial cells HUVEC, with IC50 values of 95.13±19.44 μg/mL and 112±20.77 μg, respectively) milliliter) [1].
In vitro, Pogostone has demonstrated potent antibacterial activity against both Gram-negative and Gram-positive bacteria, with a MIC of 0.098 µg/ml against Corynebacterium xerosis. It exhibits immunosuppressive properties by directly blocking T cell proliferation and altering inflammatory cytokine profiles. It induces apoptosis and autophagy in cancer cells. It has anti-inflammatory, antimicrobial, antioxidant, and anticancer activities. These activities confirm its potential for infectious disease, immunology, and cancer research. |
| ln Vivo |
In vivo antibacterial efficacy against Escherichia coli (E. coli) and MRSA is demonstrated by pogostone (intraperitoneal injection; 25, 50, and 100 mg/kg). 90% protection against E. Col infection was given at dosages of 50 and 100 mg/kg and 60% protection at 25 mg/kg, however mice infected with MRSA infection only received 60% protection. and 50% at 100 and 50 mg/kg dosages, respectively[2].
In vivo, Pogostone has been studied for its antibacterial, immunosuppressive, anti-inflammatory, and anticancer effects. Its ability to block T cell proliferation and alter cytokine profiles suggests potential for treating immune-related disorders. Its antibacterial activity suggests potential for treating infections. Its neuroprotective effects suggest potential for neurological research. However, detailed in vivo efficacy and safety data are described in the primary literature. The compound is intended for research use only. |
| Enzyme Assay |
For in vitro biochemical assays, Pogostone is evaluated for its antibacterial and immunosuppressive activities. Minimum inhibitory concentration (MIC) is determined using broth microdilution or agar dilution methods against bacterial strains. T cell proliferation is assessed using [3H]-thymidine incorporation or CFSE dilution assays. Inflammatory cytokine profiles are measured by ELISA or multiplex assays. Apoptosis and autophagy are assessed by measuring caspase activity, LC3-II conversion, and p62 levels. These cell-free and cell-based assays help characterize the compound's multiple biological activities.
|
| Cell Assay |
In vitro cellular assays for Pogostone are performed using various cell types including bacteria, T cells, and cancer cells. Bacteria are cultured in appropriate media and treated with the compound at various concentrations to determine MIC values. T cells are cultured and treated with the compound, and proliferation is assessed. Inflammatory cytokine production is measured by ELISA. Cancer cell viability is assessed using MTT or CCK-8 assays. Apoptosis is evaluated by measuring caspase activity and Annexin V/PI staining. Autophagy is assessed by measuring LC3-II conversion and p62 levels. These cellular assays help validate the compound's antibacterial, immunosuppressive, and anticancer activities.
|
| Animal Protocol |
In vivo animal experiments with Pogostone are conducted in models of infection, inflammation, and cancer. For antibacterial studies, infection models are used. For immunosuppressive studies, models of immune-mediated diseases are used. For anticancer studies, tumor xenograft models are employed. Pogostone is administered via oral gavage, intraperitoneal injection, or topical application. Efficacy endpoints include bacterial load reduction, immune response modulation, tumor growth inhibition, and survival. Researchers should consult the primary literature for detailed protocols.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Pogostone have been partially characterized. As a small molecule with a molecular weight of 224.25, it is expected to have moderate oral bioavailability and good tissue distribution. The compound is soluble in organic solvents. Detailed PK parameters such as half-life, Cmax, Tmax, AUC, and protein binding are not extensively documented. The compound should be stored under recommended conditions to maintain stability.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Pogostone is not extensively characterized. As a natural compound from patchouli oil, it is generally considered to have a moderate safety profile, but comprehensive toxicity studies are limited. The compound is intended for research use only and not for human therapeutic applications. Its immunosuppressive properties suggest potential for immune-related side effects at high doses. Researchers should follow standard laboratory safety practices when handling Pogostone.
|
| References | |
| Additional Infomation |
Dhelwangin is an aromatic ketone. It has been reported that Dhelwangin exists in Pogostemon cablin, a plant in the genus Pogostemon, and relevant data is available for reference.
Pogostone is a valuable research tool for studying antibacterial agents, immunosuppression, and anticancer mechanisms. Its potent antibacterial activity against both Gram-negative and Gram-positive bacteria, including Corynebacterium xerosis (MIC = 0.098 µg/ml), makes it useful for investigating antibacterial mechanisms and developing new antibiotics. Its immunosuppressive property through T cell blockade provides opportunities for studying immune regulation and developing immunosuppressive therapies. Its induction of apoptosis and autophagy makes it relevant for cancer research. As a component of patchouli oil, it is also important for natural product chemistry and quality control of essential oils. |
| Molecular Formula |
C12H16O4
|
|---|---|
| Molecular Weight |
224.2530
|
| Exact Mass |
224.105
|
| Elemental Analysis |
C, 64.27; H, 7.19; O, 28.54
|
| CAS # |
23800-56-8
|
| PubChem CID |
54695756
|
| Appearance |
White to off-white solid powder
|
| Density |
1.185±0.06 g/cm3 (20 ºC 760 Torr)
|
| Boiling Point |
348.2±42.0 ºC (760 Torr)
|
| Melting Point |
41 - 41.6 °C
|
| Flash Point |
129.9±21.4 ºC
|
| LogP |
2.272
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
16
|
| Complexity |
375
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C([H])([H])[H])=C([H])C(=C(C1=O)C(C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)O[H]
|
| InChi Key |
AJFJTORMMHWKFW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H16O4/c1-7(2)4-5-9(13)11-10(14)6-8(3)16-12(11)15/h6-7,14H,4-5H2,1-3H3
|
| Chemical Name |
4-hydroxy-6-methyl-3-(4-methylpentanoyl)pyran-2-one
|
| Synonyms |
Pogostone
|
| HS Tariff Code |
Solid powder
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~445.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (11.15 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (11.15 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4593 mL | 22.2965 mL | 44.5931 mL | |
| 5 mM | 0.8919 mL | 4.4593 mL | 8.9186 mL | |
| 10 mM | 0.4459 mL | 2.2297 mL | 4.4593 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
